[A24-74] Fruquintinib (colorectal cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 28.11.2024
Project no.:
A24-74
Commission:
Commission awarded on 10.07.2024 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Monotherapy for the treatment of adults with metastatic colorectal cancer who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents, and anti-epidermal growth factor receptor agents, and who have progressed on or are intolerant to treatment with either trifluridine/tipiracil or regorafenib
Hint of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2024-10-15.
https://doi.org/10.60584/A24-74_V1.1_en